Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nafamostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.63 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.63 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.63 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.63 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.63 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.63 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.63 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.63 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.63 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.63 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.63 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.63 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.63 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.63 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.63 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.63 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.63 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | KLKB1 known ✓ | P03952 | 8/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL29429445 | 0.99 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL16069975 | 0.99 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL29429443 | 0.99 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL135503 | 0.99 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL7345508 | 0.96 | PRSS1 (0.62) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL7051240 | 0.93 | PLAU (0.58) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL874941 | 0.93 | FTO (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL564665 | 0.93 | FTO (0.70) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL1568755 | 0.93 | FTO (0.70) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL29832433 | 0.93 | FTO (0.70) | PRSS1PLGF2F12KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129056-A1 | TREATMENT FOR RESPIRATORY DISEASE | Mucokinetica Ltd. (GB) | 2017-02-15 | — | — | EP | claimed |
| US-20170020838-A1 | TREATMENT FOR RESPIRATORY DISEASE | MUCOKINETICA LIMITED (GB) | 2017-01-26 | — | — | US | claimed |
| WO-2015155515-A1 | TREATMENT FOR RESPIRATORY DISEASE | MUCOKINETICA LIMITED (GB) | 2015-10-15 | — | — | WO | claimed |
| EP-2124926-B1 | Treatment for respiratory disease | MUCOKINETICA LTD (GB) | 2013-09-25 | — | — | EP | claimed |
| US-20100092402-A1 | TREATMENT OF RESPIRATORY DISEASE | MUCOKINETICA LTD. (GB) | 2010-04-15 | — | — | US | claimed |
| EP-2124926-A1 | TREATMENT FOR RESPIRATORY DISEASE | Mucokinetica Ltd. (GB) | 2009-12-02 | — | — | EP | claimed |
| WO-2008090366-A1 | TREATMENT FOR RESPIRATORY DISEASE | MUCOKINETICA LTD. (GB) | 2008-07-31 | — | — | WO | claimed |
| US-20220193021-A1 | COMBINATION THERAPY FOR TREATING INFLUENZA VIRUS INFECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2020227004-A1 | COMBINATION THERAPY FOR TREATING INFLUENZA VIRUS INFECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3129056-A1 | TREATMENT FOR RESPIRATORY DISEASE | Mucokinetica Ltd. (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-20170020838-A1 | TREATMENT FOR RESPIRATORY DISEASE | MUCOKINETICA LIMITED (GB) | 2017-01-26 | — | — | US | disclosed |
| WO-2015155515-A1 | TREATMENT FOR RESPIRATORY DISEASE | MUCOKINETICA LIMITED (GB) | 2015-10-15 | — | — | WO | disclosed |
| EP-2124926-B1 | Treatment for respiratory disease | MUCOKINETICA LTD (GB) | 2013-09-25 | — | — | EP | disclosed |
| US-20100092402-A1 | TREATMENT OF RESPIRATORY DISEASE | MUCOKINETICA LTD. (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2124926-A1 | TREATMENT FOR RESPIRATORY DISEASE | Mucokinetica Ltd. (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008090366-A1 | TREATMENT FOR RESPIRATORY DISEASE | MUCOKINETICA LTD. (GB) | 2008-07-31 | — | — | WO | disclosed |
| EP-0048433-B1 | NOVEL AMIDINE COMPOUNDS, PROCESS FOR PRODUCING SAME AND ANTI-COMPLEMENT AGENT COMPRISING THEM | TORII & CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4532255-A | Amidine compounds and anticomplement agent comprising same | TORII & CO., LTD. (JP) | 1985-07-30 | — | — | US | disclosed |
| US-4454338-A | 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE | TORII & CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092402-A1 | TREATMENT OF RESPIRATORY DISEASE | OAT, HRH2, PAM | ITGB3 3689/4885CHRM2 876/4885ITGA2B 4381/4885 |
| US-20170020838-A1 | TREATMENT FOR RESPIRATORY DISEASE | NUDT1, CFTR, P2RY4 | ITGB3 4801/4885CHRM2 943/4885ITGA2B 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.